Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2401)
•••
Post by JDavenporton Dec 13, 2022 2:13pm
233 Views
Post# 35169086

Javier Cortés, M.D., Ph.D. - Connections to Bioasis & Others

Javier Cortés, M.D., Ph.D. - Connections to Bioasis & Others
Javier Cortes, M.D., Ph.D., is a member of the Bioasis Medical Advisory Board. He has a declared financial relationship with Ellipses Pharma. His many connections are listed all over the internet.
 
I am not in the remotest manner suggesting there is anything wrong with Dr. Cortes's financial relationships, but he certainly is a candidate for connections between and introductions to Bioasis, Ellipses and several other companies that have or have had relationships with Bioasis.
 
jd 
 
Note: There is an accent on the "e" in Dr. Cortes's name. I apologize for leaving it off. Stockhouse strips accented characters out of posts because they otherwise can be used to get cusswords past their profanity filters. In other words, Stockhouse does not allow full use of one of Canada's Official Languages.
 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities